Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined mRNA COVID-19 and Influenza Vaccine in Healthy Adults
NCT06178991Phase 3Completed
- Sponsor
- BioNTech SE
- Start
- Dec 2023
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) and influenza (8 cohorts), sponsored by BioNTech SE. Primary endpoints: Percentage of Participants With Any Local Reactions at 7 days, Percentage of Participants With Any Systemic Events at 7 days and 6 more. Started Dec 2023; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06178991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06178991.